CY1105341T1 - Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο - Google Patents

Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο

Info

Publication number
CY1105341T1
CY1105341T1 CY20061101241T CY061101241T CY1105341T1 CY 1105341 T1 CY1105341 T1 CY 1105341T1 CY 20061101241 T CY20061101241 T CY 20061101241T CY 061101241 T CY061101241 T CY 061101241T CY 1105341 T1 CY1105341 T1 CY 1105341T1
Authority
CY
Cyprus
Prior art keywords
neurotransmitters
parkinson
brain
disease
treatment
Prior art date
Application number
CY20061101241T
Other languages
English (en)
Inventor
Jesus Benavides
Daniel Boccio
Yvette Henin
Odile Piot-Grosjean
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of CY1105341T1 publication Critical patent/CY1105341T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στον συνδυασμό ενός ή περισσοτέρων ανταγωνιστών CB1 παραγώγων αζετιδίνης και ενός ή περισσοτέρων χημικών προϊόντων, τα οποία διεγείρουν τους νευροδιαβιβαστές του ντοπαμινεργικού συστήματος στον εγκέφαλο, τις φαρμακευτικές ενώσεις που τα περιέχουν και τη χρήση τους για τη θεραπεία της νόσου του Πάρκινσον.
CY20061101241T 2001-08-29 2006-08-31 Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο CY1105341T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0111200A FR2829028B1 (fr) 2001-08-29 2001-08-29 Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
PCT/FR2002/002946 WO2003020314A1 (fr) 2001-08-29 2002-08-28 Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau

Publications (1)

Publication Number Publication Date
CY1105341T1 true CY1105341T1 (el) 2010-03-03

Family

ID=8866792

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101241T CY1105341T1 (el) 2001-08-29 2006-08-31 Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο

Country Status (16)

Country Link
US (2) US7217705B2 (el)
EP (2) EP1649849A3 (el)
JP (2) JP2005505551A (el)
AR (1) AR036302A1 (el)
AT (1) ATE328609T1 (el)
AU (2) AU2002337277B2 (el)
CA (1) CA2458348A1 (el)
CY (1) CY1105341T1 (el)
DE (1) DE60212148T2 (el)
DK (1) DK1423145T3 (el)
ES (1) ES2263816T3 (el)
FR (1) FR2829028B1 (el)
IL (2) IL160557A0 (el)
MX (1) MXPA04001645A (el)
PT (1) PT1423145E (el)
WO (1) WO2003020314A1 (el)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041479A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
DE10043321B4 (de) * 2000-08-24 2005-07-28 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7141669B2 (en) 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7485732B2 (en) 2003-06-11 2009-02-03 Merck & Co., Inc. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10359528A1 (de) 2003-12-18 2005-07-28 Schwarz Pharma Ag (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
WO2005077897A1 (en) * 2004-02-17 2005-08-25 Laboratorios Del Dr. Esteve S.A. Substituted azetidine compounds, their preparation and use as medicaments
ES2244314B1 (es) * 2004-02-17 2007-02-01 Laboratorios Del Dr. Esteve, S.A. Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos.
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
AU2006264649A1 (en) 2005-06-30 2007-01-11 Prosidion Limited GPCR agonists
US20070060638A1 (en) * 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
TWI392670B (zh) * 2006-06-22 2013-04-11 Ucb Pharma Gmbh 經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
GB0700122D0 (en) 2007-01-04 2007-02-14 Prosidion Ltd GPCR agonists
WO2008081208A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
WO2008081204A1 (en) 2007-01-04 2008-07-10 Prosidion Limited Piperidine gpcr agonists
AR064736A1 (es) 2007-01-04 2009-04-22 Prosidion Ltd Agonistas de gpcr
CL2008000018A1 (es) 2007-01-04 2008-08-01 Prosidion Ltd Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
GB0720390D0 (en) 2007-10-18 2007-11-28 Prosidion Ltd G-Protein coupled receptor agonists
GB0720389D0 (en) 2007-10-18 2008-11-12 Prosidion Ltd G-Protein Coupled Receptor Agonists
MX2010005925A (es) * 2007-11-28 2010-08-02 Ucb Pharma Gmbh Nueva forma polimorfico de rotigotina y proceso para la produccion.
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
TW201105665A (en) 2009-04-22 2011-02-16 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2281559A1 (en) 2009-06-26 2011-02-09 UCB Pharma GmbH Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
SI2515887T1 (sl) 2009-12-22 2018-10-30 Ucb Biopharma Sprl Polivinilpirolidon za stabilizacijo trdne disperzije nekristalinične oblike rotigotina
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
AU2011316975A1 (en) * 2010-10-22 2013-05-23 Janssen Pharmaceutica Nv Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
US9248111B2 (en) * 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
WO2022245900A2 (en) * 2021-05-21 2022-11-24 Murphy Brian Stuart Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5635159A (en) * 1994-08-26 1997-06-03 Abbott Laboratories Aerosol drug formulations containing polyglycolyzed glycerides
US5562917A (en) * 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
WO2001041808A1 (fr) * 1999-12-10 2001-06-14 Takeda Chemical Industries, Ltd. Compositions medicinales a usage par voie orale
US6355631B1 (en) * 2000-03-03 2002-03-12 Aventis Pharma S.A. Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation

Also Published As

Publication number Publication date
FR2829028B1 (fr) 2004-12-17
JP2010053153A (ja) 2010-03-11
US7217705B2 (en) 2007-05-15
ES2263816T3 (es) 2006-12-16
AU2002337277B2 (en) 2008-06-05
EP1649849A3 (fr) 2006-11-02
EP1649849A2 (fr) 2006-04-26
IL193325A0 (en) 2009-02-11
MXPA04001645A (es) 2004-05-31
US20070197654A1 (en) 2007-08-23
DE60212148D1 (de) 2006-07-20
IL160557A0 (en) 2004-07-25
EP1423145B1 (fr) 2006-06-07
AU2008212039A1 (en) 2008-10-09
JP2005505551A (ja) 2005-02-24
DE60212148T2 (de) 2007-04-19
EP1423145A1 (fr) 2004-06-02
US20040209861A1 (en) 2004-10-21
WO2003020314A1 (fr) 2003-03-13
PT1423145E (pt) 2006-09-29
FR2829028A1 (fr) 2003-03-07
AR036302A1 (es) 2004-08-25
ATE328609T1 (de) 2006-06-15
CA2458348A1 (en) 2003-03-13
DK1423145T3 (da) 2006-10-02

Similar Documents

Publication Publication Date Title
CY1105341T1 (el) Συνθεσεις για τη θepαπεια της νοσου του παρκινσον, οι οποιες πepιεχουν εναν ανταγωνιστη του υποδοχεα cb1 και ενα χημικο προϊον που διεγειρει τους νευροδιαβιβαστες του ντοπαμινepγικου συστηματος στον εγκεφαλο
CY1105879T1 (el) Αζαδικυκλο παραγωγα ως ανταγωνιστες μουσκαρινικου υποδοχεα
CY1106386T1 (el) Υποκατεστημενα παραγωγα 3-πυρρολιδιν-ινδολης
JO2371B1 (en) 4-phenyl-pyridine derivatives
GEP20063741B (en) Nonaryl-Heterocyclic NMDA/NR2B Antagonists
IS6922A (is) Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum
MXPA04012393A (es) Derivados de piperazina 1-aril-4-substituidos para utilizar como antagonistas ccr1 para tratamiento de inflamacion y desordenes inmunes.
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
NO20062303L (no) Pyrazinderivater og farmasoytisk anvendelse derav
CY1105000T1 (el) Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη
GEP20074197B (en) 5ht2c receptor modulators
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
CY1113039T1 (el) Ηλεκτρικο και μηλονικο αλας τρανς-4-(1r,3s)-6-χλωρο-3-φαινυλινδαν-1-υλο)-1,2,2-τριμεθυλοπιπεραζινης και η χρηση ως φαρμακο
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
AR035348A1 (es) Indoles sustituidos, composiciones farmaceuticas que los comprenden, y uso de dichos compuestos en la preparacion de medicamentos
MXPA04001848A (es) Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson.
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
CY1105746T1 (el) Eνωσεις που επηρεαζουν τη γλυκοκιναση
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
TW200800946A (en) Substituted piperazines as metabotropic glutamate receptor antagonists
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
CY1105028T1 (el) Υποκατεστημενες c-ιμιδαζο-[1,2-α]πυριδιν-3-υλο-μεθυλαμινες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν